A cell-based immunotherapy that’s designed to overcome the defense mechanisms that help ovarian cancer evade treatment was highly effective at killing cancer cells in preclinical…
News
The European Union (EU) expanded its approval of Sarclisa (isatuximab-irfc), making it available to newly diagnosed adults with multiple myeloma who are eligible for…
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people…
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
The U.S. Food and Drug Administration (FDA) granted fast track designation to birelentinib as a potential treatment for certain forms of blood cancer. The…
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.
